Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma

被引：29

作者：

Chen, Robert ^{[1
]}

Palmer, Joycelynne M. ^{[2
]}

Popplewell, Leslie ^{[1
]}

Shen, Jessica ^{[2
]}

Smith, Eileen ^{[1
]}

Delioukina, Maria ^{[1
]}

Kogut, Neil ^{[3
]}

Rosenthal, Joseph ^{[4
]}

Forman, Stephen ^{[1
]}

Nademanee, Auayporn ^{[1
]}

机构：

[1] City Hope Natl Med Ctr, Dept Hematol Hematopoiet Cell Transplantat, Duarte, CA 91010 USA

[2] City Hope Natl Med Ctr, Div Biostat, Duarte, CA 91010 USA

[3] City Hope Kaiser Permanente, Los Angeles, CA USA

[4] City Hope Natl Med Ctr, Dept Pediat Hematopoiet Cell Transplantat, Duarte, CA 91010 USA

来源：

ANNALS OF HEMATOLOGY | 2011年 / 90卷 / 07期

关键词：

Allogeneic transplant; Reduced intensity; Hodgkin lymphoma; Relapsed; HL; BONE-MARROW TRANSPLANT; SALVAGE THERAPY; PHASE-II; DISEASE; TRIAL; REGIMEN; CHEMOTHERAPY; GEMCITABINE; EXPERIENCE; HYBRID;

D O I：

10.1007/s00277-010-1146-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hodgkin lymphoma (HL) can be aggressive and intractable in some cases. Patients who relapse after autologous HCT (auto-HCT) have limited treatment options. City of Hope reports our experience in the use of reduced intensity allogeneic hematopoietic cell transplantation (allo-HCT) in 24 heavily pretreated patients with relapsed HL, between January 2003 and December 2008. The median number of prior therapies was 5; 20/24 patients had prior auto-HCT. The conditioning regimen for all patients was fludarabine and melphalan. With a median follow-up for living patients of 39.0 months, at 2 years the overall survival (OS) was 60% (95% CI 42, 72) and the progression-free survival was 27% (95% CI 22, 32). Non-relapse mortality was 13.1% (95% CI 5.1, 31.4) at 2 years. The incidence of grade II-IV aGVHD was 45.8% and 8.3% for grade III-IV. Allo-HCT in heavily pretreated relapsed Hodgkin lymphoma is feasible, tolerable, and can induce durable clinical remissions.

引用

页码：803 / 808

页数：6

共 30 条

[1] Fludarabine-meiphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience [J].

Anderlini, Paolo ;

Saliba, Rima ;

Acholonu, Sandra ;

Giralt, Sergio A. ;

Andersson, Borje ;

Ueno, Naoto T. ;

Hosing, Chitra ;

Khouri, Issa F. ;

Couriel, Daniel ;

de Lima, Marcos ;

Qazilbash, Muzaffar H. ;

Pro, Barbara ;

Romaguera, Jorge ;

Fayad, Luis ;

Hagemeister, Frederick ;

Younes, Anas ;

Munsell, Mark F. ;

Champlin, Richard E. .

HAEMATOLOGICA, 2008, 93 (02) :257-264

[2] ALLOGENEIC, SYNGENEIC, AND AUTOLOGOUS MARROW TRANSPLANTATION FOR HODGKINS-DISEASE - THE 21-YEAR SEATTLE EXPERIENCE [J].

ANDERSON, JE ;

LITZOW, MR ;

APPELBAUM, FR ;

SCHOCH, G ;

FISHER, LD ;

BUCKNER, CD ;

PETERSEN, FB ;

CRAWFORD, SW ;

PRESS, OW ;

SANDERS, JE ;

BENSINGER, WI ;

MARTIN, PJ ;

STORB, R ;

SULLIVAN, KM ;

HANSEN, JA ;

THOMAS, ED .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2342-2350

[3] Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: Importance of histology for outcome [J].

Armand, Philippe ;

Kim, Haesook T. ;

Ho, Vincent T. ;

Cutler, Corey S. ;

Koreth, John ;

Antin, Joseph H. ;

LaCasce, Ann S. ;

Jacobsen, Eric D. ;

Fisher, David C. ;

Brown, Jennifer R. ;

Canellos, George P. ;

Freedman, Arnold S. ;

Soiffer, Rohert J. ;

Alyea, Edwin P. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (04) :418-425

[4] Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group [J].

Baetz, T ;

Belch, A ;

Couban, S ;

Imrie, K ;

Yau, J ;

Myers, R ;

Ding, K ;

Paul, N ;

Shepherd, L ;

Iglesias, J ;

Meyer, R ;

Crump, M .

ANNALS OF ONCOLOGY, 2003, 14 (12) :1762-1767

[5] Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning [J].

Baron, F ;

Little, MT ;

Storb, R .

BLOOD REVIEWS, 2005, 19 (03) :153-164

[6] Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804 [J].

Bartlett, N. L. ;

Niedzwiecki, D. ;

Johnson, J. L. ;

Friedberg, J. W. ;

Johnson, K. B. ;

van Besien, K. ;

Zelenetz, A. D. ;

Cheson, B. D. ;

Canellos, G. P. .

ANNALS OF ONCOLOGY, 2007, 18 (06) :1071-1079

[7]

Breslow N E, 1987, IARC Sci Publ, P1

[8] Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines [J].

Buglio, Daniela ;

Georgakis, Georgios V. ;

Hanabuchi, Shino ;

Arima, Kazuhiko ;

Khaskhely, Noor M. ;

Liu, Yong-Jun ;

Younes, Anas .

BLOOD, 2008, 112 (04) :1424-1433

[9] Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma [J].

Burroughs, Lauri M. ;

O'Donnell, Paul V. ;

Sandmaier, Brenda M. ;

Storer, Barry E. ;

Luznik, Leo ;

Symons, Heather J. ;

Jones, Richard J. ;

Ambinder, Richard F. ;

Maris, Michael B. ;

Blume, Karl G. ;

Niederwieser, Dietger W. ;

Bruno, Benedetto ;

Maziarz, Richard T. ;

Pulsipher, MichaelA. ;

Petersen, Finn B. ;

Storb, Rainer ;

Fuchs, Ephraim J. ;

Maloney, David G. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (11) :1279-1287

[10] Long-term follow-up of Hodgkin's disease trial [J].

Canellos, GP ;

Niedzwiecki, D .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (18) :1417-1418

← 1 2 3 →